13 Jun 2012 17:51
For immediate release | 13 June 2012 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director's Dealings
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that the Company was notified on 13 June 2012 that Anthony Richard Booley, a Director of the Company, sold 1.4 million shares on 13 June 2012 at 27 pence per share. Following these transactions, Mr Booley holds 5,410,723 Ordinary Shares in the Company, representing approximately 2.25% of the issued share capital.
The sale has been made in order to enable Mr Booley to settle a capital gains tax liability to HM Revenue and Customs.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive | |
Richard Wright, Finance Director | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Oliver Cardigan | |
Corporate Broking: David Poutney |
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Alliance Pharma (APH)